You are here: Industry Insights > Bristol-Myers Squibb

News List

Bristol-Myers Squibb's Opdivo fails 3rd straight test in tough-to-treat brain cancer fiercepharma
September 08, 2019
Bristol-Myers Squibb has once again come up empty-handed in one of the world’s deadliest and toughest-to-treat cancers.
Megadeals aside, pharma M&A actually dropped in the first half of 2019 fiercepharma
August 01, 2019
When Bristol-Myers Squibb kicked off 2019 by making a $74 billion bid for Celgene, biopharma watchers everywhere declared it to be the end of the mergers-and-acquisitions drought in the sector.
Bristol-Myers Squibb, Bayer team up on Opdivo-Stivarga combo in colorectal cancer fiercepharma
July 20, 2019
Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.
Bayer, Bristol-Myers Squibb, Ono Pharmaceutical to Investigate Stivarga, Opdivo Combo Therapy americanpharmaceuticalreview
July 19, 2019
Bayer, Bristol-Myers Squibb, and Ono Pharmaceutical announced the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga® (regorafenib) and ...
In a crowded psoriasis field, who could nab Celgene’s Otezla—and at what price? fiercepharma
July 04, 2019
Antitrust regulators recently surprised industry watchers with the stipulation that Bristol-Myers Squibb sell Celgene's Otezla to win U.S. clearance for its $74 billion merger.
Bristol-Myers Squibb's Opdivo fails to hit survival goal in study of patients with newly diagnosed MGMT-unmethylated glioblastoma multiforme firstwordpharma
May 10, 2019
Bristol-Myers Squibb said Thursday that a Phase III study evaluating Opdivo (nivolumab) plus radiation versus temozolomide plus radiation in patients with newly diagnosed MGMT-unmethylated glioblastoma multiforme (GBM) failed to ...
Don't worry about our $19B bond issue, BMS says. With Celgene, we'll have the cash to pay it off fiercepharma
May 09, 2019
Bristol-Myers Squibb is taking on a debt load to cover its $74 billion Celgene buyout, and it issued $19 billion in bonds Tuesday to help pay the bill.
Bristol-Myers Squibb reports first quarter financial results April 26, 2019
Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by s
Bristol-Myers Squibb, Celgene shareholders vote to back proposed $74-billion merger firstwordpharma
April 14, 2019
Shareholders have voted to approve Bristol-Myers Squibb's roughly $74-billion deal to acquire Celgene, the companies announced separately on Friday.
Bristol-Myers Squibb denies defensive strategy firstwordpharma
March 15, 2019
In a note to investors published late last week, Wolfe Research analyst Tim Anderson suggested that when probed by sell-side analysts, Bristol-Myers Squibb management has so far “stopped short of saying whether there has been any informal indication of in

Previous page 1 2 3 4 5 6 7 8 9 10 Next page